Posted by Michael Wonder on 09 Jun 2020
Insmed receives FDA breakthrough therapy designation for brensocatib in patients with non-cystic fibrosis bronchiectasis
8 June 2020 - Full results from phase 2 WILLOW study of brensocatib in non-cystic fibrosis bronchiectasis to be presented at virtual ATS session on 24 June 2020.
Insmed today announced that the U.S. FDA has granted breakthrough therapy designation for brensocatib (formerly known as INS1007) for the treatment of adult patients with non-cystic fibrosis bronchiectasis for reducing exacerbations.
Brensocatib is a novel oral, reversible inhibitor of dipeptidyl peptidase 1 currently being developed by Insmed for the treatment of bronchiectasis and other inflammatory diseases.
